Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Respiratory mechanics assessment Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study

NCT01571037
View directory record Official record
Conditions
End Stage Heart Disease, Right Ventricular Dysfunction
Interventions
inhaled nebulized milrinone
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

NCT00503490
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin solution for Inhalation), placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
16 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
14
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Results available

Inhaled Tobramycin in BPD

NCT04560179
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose
Drug
Lead sponsor
Erik Allen Jensen
Other
Eligibility
4 Weeks and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

Veteran Support and Resources for Diabetes

NCT04041375
View directory record Official record
Conditions
Diabetes
Interventions
iNSPiRED, Usual Care
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Sep 25, 2026, 4:13 PM EDT
Completed No phase listed Observational

Chest Wall Influence on Respiratory System Mechanics in Morbidly Obese Patients

NCT02105220
View directory record Official record
Conditions
Obesity, Intra-Abdominal Hypertension
Interventions
Respiratory mechanics assessment
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 25, 2026, 4:13 PM EDT
Recruiting No phase listed Observational

EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation

NCT06212791
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Self- Report Evaluation-Duke Activity Status Index, Self- Report Evaluation Atrial Fibrillation Effect on Quality of Life Questionnaire, Cardiopulmonary exercise test (CPET), Transthoracic echocardiogram, Ambulatory cardiac rhythm assessment, Cardiovascular magnetic resonance (CMR)
Behavioral · Diagnostic Test
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 25, 2026, 4:13 PM EDT
Completed No phase listed Observational

Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations

NCT01482923
View directory record Official record
Conditions
Tobacco Cessation, HIV, AIDS
Interventions
Treatment as usual, AIR (Aspirations, Inspiration, Respiration)
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 25, 2026, 4:13 PM EDT
Active, not recruiting No phase listed Observational

Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

NCT04537871
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Bioelectric Impedance Analysis, Biospecimen Collection, Cardiopulmonary Exercise Testing, Echocardiography, Physical Performance Testing, Pulmonary Function Test, Questionnaire Administration, Ultrasound
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-3)

NCT01515007
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Peoria, Arizona • Phoenix, Arizona • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Not applicable Interventional

Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis

NCT00546663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled 7% hypertonic saline (HS)
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
12 Months to 30 Months
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00752414
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
MP-376 (Levofloxacin solution for Inhalation), Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Mobile, Alabama • Phoenix, Arizona • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

NCT00388505
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder, Tobramycin Solution for Inhalation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
24
States / cities
Hartford, Connecticut • Atlanta, Georgia • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2012 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing

NCT00626028
View directory record Official record
Conditions
Idiopathic Pulmonary Arterial Hypertension, Cardiomyopathy
Interventions
Nitric Oxide for inhalation, Oxygen, Nitric Oxide plus Oxygen
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
4 Weeks to 18 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
8
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 25, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)

NCT03963622
View directory record Official record
Conditions
ARDS
Interventions
Respiratory Mechanics, Standard Ventilation Strategy
Other
Lead sponsor
Unity Health Toronto
Other
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 25, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Ventilator Pressure and Optimization of Compliance and Hemodynamics

NCT06512935
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions
Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Days to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

NCT00889967
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin for Inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 25, 2026, 4:13 PM EDT
Terminated Not applicable Interventional

Stress Index to Individualize Mechanical Ventilation in ARDS

NCT02871102
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Recruitment Maneuver with PEEP and Tidal Volume Optimization
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

NCT00840333
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
MP-376 (Levofloxacin solution for Inhalation)
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 16 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Mobile, Alabama • San Diego, California • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 25, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

NCT02528318
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant for inhalation, nCPAP alone
Combination Product · Device
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
26 Weeks to 28 Weeks
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Loma Linda, California • San Diego, California • Newark, Delaware + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

NCT02679729
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZD5634 for inhalation, AZD5634 for infusion, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

NCT03084796
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
CHF 5259, Placebo, Tiotropium Bromide 18 µg Inhalation Capsule
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
112
States / cities
Birmingham, Alabama • Dothan, Alabama • Montgomery, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Sep 25, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

NCT02074059
View directory record Official record
Conditions
Respiratory Distress Syndrome
Interventions
Lucinactant for Inhalation, nCPAP alone
Drug · Device
Lead sponsor
Windtree Therapeutics
Industry
Eligibility
29 Weeks to 34 Weeks
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 25, 2026, 4:13 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 25, 2026, 4:13 PM EDT